Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and safety of S066913 in paroxysmal atrial fibrillation (randomized, double blind, placebo-controlled, phase 2)
2014-002333-63Phase 2Terminated
- Sponsor
- Servier
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of S066913 in Atrial fibrillation (AFib) (4 arms), sponsored by Servier. Primary endpoint: Change from baseline in AF/AT burden. Started Aug 2014; status: terminated.
02
Drugs
S066913
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2014-002333-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002333-63.